A Novel M2e Based Flu Vaccine Formulation for Dogs

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Leclerc, Denis ^a   Rivest, Marie ^a   Babin, Cindy ^a   López Macias, Constantino ^b   Savard, Pierre ^c  

^a LAVAL UNIVERSITY   (Canada)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COAT PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHIONYLSERYLLEUCYLLEUCYLTHREONYLGLUTAMYLVALYLGLUTAMYLTHREONYLPROLYLTHREONYLARGINYLASPARAGINYLGLYCYLTRYPTOPHANYLGLUTAMYLCYSTEINYLLYSYLCYSTEINYLSERYLASPARTYLSERYLSERYLASPARTIC ACID; NANOPARTICLE; OUTER MEMBRANE PROTEIN C; OUTER MEMBRANE PROTEIN F; PEPTIDE VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSS REACTION; DOG; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG STABILITY; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INFLUENZA; INFLUENZA VIRUS A H3N8; MALVA MOSAIC VIRUS; MOUSE; NONHUMAN; POTEXVIRUS; SALMONELLA TYPHI; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CONSERVED SEQUENCE; CROSS PROTECTION; DOG DISEASES; DOGS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N8 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MOSAIC VIRUSES; NANOPARTICLES; ORTHOMYXOVIRIDAE INFECTIONS; PORINS; VACCINATION; VIRAL ENVELOPE PROTEINS;

EID: 84884880714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077084     Document Type: Article

References (42)

1. Crawford PC, Dubovi EJ, Castleman WL, Stephenson I, Gibbs EP, (2005) Transmission of equine influenza virus to dogs. Science 310: 482-486. doi:10.1126/science.1117950. PubMed: 16186182.
2. Deshpande MS, Jirjis FF, Tubbs AL, Jayappa H, Sweeney D, et al. (2009) Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge. Vet Ther 10: 103-112. PubMed: 20037964.
3. Daly JM, Blunden AS, Macrae S, Miller J, Bowman SJ, et al. (2008) Transmission of equine influenza virus to english foxhounds. Emerg Infect Dis 14: 661-464. doi:10.3201/eid1404.060570. PubMed: 18394289.
4. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W, (2004) A 'Universal' human influenza A vaccine. Virus Res 103: 173-176. doi:10.1016/j.virusres.2004.02.030. PubMed: 15163506.
5. Lamb RA, Zebedee SL, Richardson CD, (1985) Influenza virus M2-protein is an integral membrane protein expressed on the infected-cell surface. Cell 40: 627-633. doi:10.1016/0092-8674(85)90211-9. PubMed: 3882238.
6. Sugrue RJ, Hay AJ, (1991) Structural characteristics of the M2-protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 180: 617-624. doi:10.1016/0042-6822(91)90075-M. PubMed: 1989386.
7. Holsinger LJ, Lamb RA, (1991) Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 183: 32-43. doi:10.1016/0042-6822(91)90115-R. PubMed: 2053285.
8. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, et al. (2008) Development of a Universal Influenza A vaccine based on the M2e peptide fused to the Papaya Mosaic Virus (PapMV) vaccine platform. Vaccine 26: 3395-3403. doi:10.1016/j.vaccine.2008.04.052. PubMed: 18511159.
9. De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, et al. (2008) Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 26: 6503-6507. doi:10.1016/j.vaccine.2008.09.038. PubMed: 18835315.
10. Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, et al. (2009) Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27: 1440-1447. doi:10.1016/j.vaccine.2008.12.034. PubMed: 19146898.
11. Tissot AC, Renhofa R, Schmitz N, Cielens I, Meijerink E, (2010) Versatile virus-like particle carrier for epitope based vaccines. PLOS ONE 5: e9809. doi:10.1371/journal.pone.0009809. PubMed: 20352110.
12. Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, (2011) Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLOS ONE 6: e14538. doi:10.1371/journal.pone.0014538. PubMed: 21267073.
13. Matić S, Rinaldi R, Masenga V, Noris E, (2011) Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol 11: 106. doi:10.1186/1472-6750-11-106. PubMed: 22085463.
14. Gao X, Wang W, Li Y, Zhang S, Duan Y, (2013) Enhanced Influenza VLP vaccines comprising matrix-2 ectodomainand nucleoprotein epitopes protects mice from lethal challenge. Antiviral Res 98: 4-11. doi:10.1016/j.antiviral.2013.01.010. PubMed: 23416215.
15. Kim MC, Song JM, O E, Kwon YM, Lee YJ, (2013) Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 21: 485-492. doi:10.1038/mt.2012.246. PubMed: 23247101.
16. Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, (2012) Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLOS ONE 7: e45765. doi:10.1371/journal.pone.0045765. PubMed: 23029232.
17. Ebrahimi SM, Tebianian M, (2011) Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 42: 1-8. doi:10.1007/s11262-010-0547-7. PubMed: 21082230.
18. O'Hagan DT, De Gregorio E, (2010) The path for a successful vaccine adjuvant-'The long and the winding road'. Drug Discov Today 14: 541-551.
19. Cervantes-Barragán L, Gil-Cruz C, Pastelin-Palacios R, Lang KS, Isibasi A, et al. (2009) TLR2 and TLR4 signaling shapes specific antibody responses to Salmonella typhi antigens. Eur J Immunol 39: 126-135. doi:10.1002/eji.200838185. PubMed: 19130558.
20. Alurkar V, Kamat R, (1997) Immunomodulatory properties of porins of some members of the family Enterobacteriaceae. Infect Immun 65: 2382-2388. PubMed: 9169778.
21. Jegerlehner A, Schmitz N, Storni T, Bachmann MF, (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody dependent NK cell activity. J Immunol 172: 5598-5605. PubMed: 15100303.
22. Seidel UJ, Schlegel P, Lang P, (2013) Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 10: 76.
23. Côté F, Paré C, Majeau N, Bolduc M, Leblanc E, et al. (2008) Nucleotide sequence and phylogenetic analysis of a new potexvirus: Malva Mosaic Virus. Infect Genet Evol 8: 83-93. doi:10.1016/j.meegid.2007.10.006. PubMed: 18054524.
24. Hanafi LA, Bolduc M, Laliberté-Gagné ME, Dufour F, Langelier Y, et al. (2010) Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes. Vaccine 28: 5617-5626. doi:10.1016/j.vaccine.2010.06.024. PubMed: 20600515.
25. Babin C, Majeau N, Leclerc D, (2013) Engineering of papaya mosaic virus (PapMV) nanoparticles with a ctl epitope derived from influenza NP. J Nanobiotechnology 11: 10. doi:10.1186/1477-3155-11-10. PubMed: 23556511.
26. Rioux G, Babin C, Majeau N, Leclerc D, (2012) Engineering of papaya mosaic virus (PapMV) nanoparticles through fusion of the HA11 peptide to several putative surface-exposed sites. PLOS ONE 7: e31925. doi:10.1371/journal.pone.0031925. PubMed: 22363771.
27. Lacasse P, Denis J, Lapointe R, Leclerc D, Lamarre A, (2008) Novel plant virus-based vaccine induces protective CTL-mediated antiviral immunity through dendritic cell maturation. J Virol 82: 785-794. doi:10.1128/JVI.01811-07. PubMed: 17989184.
28. Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bédard M-C, et al. (2007) Immunogenicity of Papaya Mosaic Virus like particles fused to a hepatitis C virus epitope: Evidence for the critical function of multimerization. Virology 363: 59-68. doi:10.1016/j.virol.2007.01.011. PubMed: 17320136.
29. Leclerc D, Beauseigle D, Denis J, Morin H, Paré C, et al. (2007) Proteasome-independent MHC class I cross-presentation mediated by papaya mosaic virus-like particles leads to the expansion of specific human T cells. J Virol 81: 1319-1326. doi:10.1128/JVI.01720-06. PubMed: 17121795.
30. Lico C, Capuano F, Renzone G, Donini M, Marusic C, et al. (2006) Peptide display on Potato virus X: molecular features of the coat protein-fused peptide affecting cell-to-cell and phloem movement of chimeric virus particles. J Gen Virol 87: 3103-3112. doi:10.1099/vir.0.82097-0. PubMed: 16963770.
31. Marusic C, Rizza P, Lattanzi L, Mancini C, Spada M, et al. (2001) Chimeric Plant Virus Particles as Immunogens for Inducing Murine and Human Immune Responses against Human Immunodeficiency Virus Type 1. J Virol 75: 8434-8439. doi:10.1128/JVI.75.18.8434-8439.2001. PubMed: 11507188.
32. Uhde K, Fischer R, Commandeur U, (2005) Expression of multiple foreign epitopes presented as synthetic antigens on the surface of Potato virus X particles. Arch Virol 150: 327-340. doi:10.1007/s00705-004-0402-z. PubMed: 15503224.
33. Leclerc D, (2011) Plant Viral Epitope Display Systems for Vaccine Development. Curr Top Microbiol Immunol 183: 2-13. PubMed: 22021043.
34. Savard C, Laliberté-Gagné M-È, Bolduc M, Guérin A, Drouin K, et al. (2012) Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen (Influenza NP). Vaccine 15: 2535-2542.
35. Savard C, Guérin A, Drouin K, Bolduc M, Laliberté-Gagné M-E, et al. (2011) Improvement of the Trivalent Inactivated Flu Vaccine Using PapMV Nanoparticles. PLOS ONE 6: e21522. doi:10.1371/journal.pone.0021522. PubMed: 21747909.
36. Mathieu C, Rioux G, Dumas M-C, Leclerc D, (2013) Induction of innate immunity inlungs with virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae challenge. Nanomedecine. [Epub ahead of print].
37. Stuart-Harris CH, (1939) A neurotropic strain of human influenza virus. Lancet 1: 497-499.
38. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W, (2004) A 'Universal' human influenza A vaccine. Virus Res 103: 173-176. doi:10.1016/j.virusres.2004.02.030. PubMed: 15163506.
39. Liu W, Zou P, Chen Y-H, (2004) Monoclonal antibodies recognizing EVETPIRNE epitope of influenza A virus M2 protein could protect mice from a lethal influenza A virus challenge. Immunol Lett 93: 131-136. doi:10.1016/j.imlet.2004.03.003. PubMed: 15158608.
40. Grandea AG III, Olsen OA, Cox TC, Renshaw M, Hammond PW, et al. (2010) Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A 107: 12658-12663. doi:10.1073/pnas.0911806107. PubMed: 20615945.
41. Martínez-Flores I, Cano R, Bustamante VH, Calva E, Puente JL, (1999) The ompB operon partially determines differential expression of OmpC in Salmonella typhi and Escherichia coli. J Bacteriol 181: 556-562. PubMed: 9882670.
42. Secundino I, López-Macías C, Cervantes-Barragán L, Gil-Cruz C, Ríos-Sarabia N, et al. (2006) Salmonella porins induce a sustained, lifelong specific bactericidal antibody memory response. Immunology 117: 59-70. doi:10.1111/j.1365-2567.2005.02263.x. PubMed: 16423041.